Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness
- 1 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 48 (1) , 4-9
- https://doi.org/10.1097/mlr.0b013e3181bd4c10
Abstract
Objectives: Prior authorization policies (PA) are widely used to control psychotropic medication costs by state Medicaid programs and Medicare Part D plans. The objective of this study was to examine the impact of a Maine Medicaid PA policy on initiation and switching of anticonvulsant and atypical antipsychotic treatments among patients with bipolar disorder. Methods: We obtained Maine and New Hampshire (comparison state) Medicaid and Medicare claims data for 2001 to 2004; the Maine PA policy was implemented in July 2003. Among continuously enrolled patients with bipolar disorder (Maine: n = 5336; New Hampshire: n = 1376), we used an interrupted times series with comparison group design to estimate changes in rates of initiating new episodes of bipolar treatment and generalized estimating equations models to examine rates of switching therapies among patients under treatment. Results: The Maine PA policy was associated with a marked decrease in rates of initiation of bipolar treatments; a relative reduction of 32.3% (95% CI: 24.8, 39.9) compared with expected rates at 4 months after policy implementation. This decrease was driven primarily by reductions in the initiation of nonpreferred agents. The policy had no discernable impact on rates of switching therapy among patients currently on treatment (RR: 1.03; 95% CI: 0.76, 1.39). Conclusions: The findings of this study provide evidence that PA implementation can be a barrier to initiation of nonpreferred agents without offsetting increases in initiation of preferred agents, which is a major concern. There is a critical need to evaluate the possible unintended effects of PA policies to achieve optimal health outcomes among low-income patients with chronic mental illness. In addition, more research is needed to understand how these barriers arise and whether specific seriously mentally ill populations or drug classes should be exempted from PA policies.Keywords
This publication has 24 references indexed in Scilit:
- Prior Authorization for Antidepressants in MedicaidJAMA Internal Medicine, 2009
- Methods for estimating confidence intervals in interrupted time series analyses of health interventionsJournal of Clinical Epidemiology, 2008
- Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy ChangeHealth Affairs, 2008
- National Health Spending In 2005: The Slowdown ContinuesHealth Affairs, 2007
- Differential Effect of Early or Late Implementation of Prior Authorization Policies on the Use of Cox II InhibitorsMedical Care, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Medicaid Policies To Contain Psychiatric Drug CostsHealth Affairs, 2005
- Pharmacotherapy for bipolar depression: an economic assessmentExpert Opinion on Pharmacotherapy, 2004
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994
- Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care.American Journal of Public Health, 1981